THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

19 March 2026

ECO Animal Health Group plc

("ECO" or the "Company")

Full Year Trading Update

Continued strong momentum in H2 with improved margins outperforming market expectations

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces the following unaudited trading update for the year ending 31 March 2026.

As previously announced, trading in the first half of this financial year was significantly stronger compared to the same period last year. This trend has continued to year end with an expected year-on-year increase in revenue of c.8%, slightly ahead of market expectations¹ (2025: £79.6 million). Revenue growth has been particularly strong in North America and Latin America, despite currency headwinds and tariff challenges.

The Company also expects to report improved gross margins for the year, primarily driven by improved product pricing and cost of goods. The combined effect of the stronger revenue and margins is expected to result in a material increase in adjusted EBITDA over the prior year (2025: £7.3m) with adjusted EBITDA also materially ahead of market expectations.¹ The final outcome for the full year will be subject to the usual audit process, including the customary assessment of balance sheet provisioning.

The Company expects to report its audited full year results in early July.

¹ The consensus market expectations for revenue and adjusted EBITDA for the year ending 31 March 2026 are £83.5m and £7.6m respectively.  

-Ends- 

Contacts

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin^® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

Click here for more information: https://ecoanimalhealth.com